Altering and assessing persistence of genetically modified E. coli MG1655 in the large bowel

Experimental Biology and Medicine

Volumn 234, Issue 10, 2009, Pages 1174-1185

  Barbas, Andrew S ^a   Lesher, Aaron P ^a   Thomas, Anitra D ^a   Wyse, Aaron ^a   Devalapalli, Aditya P ^a   Lee, Yu Huei ^a   Tan, Hung Enn ^a   Orndorff, Paul E ^b   Bollinger, R Randal ^a   Parker, William ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Immunoglobulin A; Pilus; Probiotics

Indexed keywords

ADHESIN; MANNOSE; PROBIOTIC AGENT; SECRETORY IMMUNOGLOBULIN; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM PILUS; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; ESCHERICHIA COLI MG 1655; FECES ANALYSIS; FEMALE; GASTROINTESTINAL DISEASE; GENE OVEREXPRESSION; IN VIVO STUDY; LARGE INTESTINE; MOUSE; NONHUMAN; STOMA; TRANSGENIC ORGANISM; WATER CONTENT;

ADHESINS, BACTERIAL; ANIMALS; BACTERIAL ADHESION; CECUM; ESCHERICHIA COLI K12; FECES; FEMALE; FIMBRIAE, BACTERIAL; IMMUNOGLOBULIN A, SECRETORY; INTESTINAL MUCOSA; INTESTINE, LARGE; MICE; MICE, INBRED STRAINS; PROBIOTICS; TIME FACTORS;

ANIMALIA; ENTEROBACTERIACEAE; MUS;

EID: 70349667604     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0812-RM-358     Document Type: Article

References (39)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546, 2003.
2. Felbinger TW, Suchner U, Goetz AE. Treating patients with severe sepsis. N Engl J Med 341:56, 1999.
3. Food and Agricultural Organization of the United Nations and the World Health Organization. Regulatory and clinical aspects of dairy products. Report of a joint FAO/WHO Expert Consultation, Cordoba, Argentina, 2001. Available at: ftp://ftp.fao.org/docrep/fao/meeting/009/y6398e.pdf
4. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomised controlled study vs. mesalazine. Gastroenterology 118:A781, 2000.
5. Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, Campieri M. Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract Res Clin Gastroenterol 17:821, 2003. (Pubitemid 37554725)
6. Gionchetti, P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli, M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. [see comment]. Gastroenterology 119:305, 2000.
7. Rayes N, Hansen S, Seehofer D, Muller AR, Serke S, Bengmark S, Neuhaus P. Early enteral supply of fiber and lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition 18:609, 2002. (Pubitemid 34687100)
8. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 6:428, 1993.
9. O'Boyle CJ, MacFie J, Mitchell CJ, Johnstone D, Sagar PM, Sedman PC. Microbiology of bacterial translocation in humans. Gut 42:29, 1998.
10. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, Bengmark S, Neuhaus P. Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 74:123, 2002. (Pubitemid 34779222)
11. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 52:385, 2007.
12. Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soule JC, Bourreille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Coffin B, Moreau J, Abitbol V, Blum-Sperisen S, Mary JY. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55:842, 2006. (Pubitemid 43764556)
13. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405, 2002. (Pubitemid 34907710)
14. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371:651, 2008.
15. Duguid JP, Clegg S, Wilson MI. The fimbrial and non-fimbrial haemagglutinins of Escherichia coli. J Med Microbiol 12:213, 1979. (Pubitemid 9203006)
16. Schembri MA, Ussery DW, Workman C, Hasman H, Klemm P. DNA microarray analysis of fim mutations in Escherichia coli. Mol Genet Genom 267:721, 2002. (Pubitemid 35013679)
17. Krogfelt KA, Bergmans H, Klemm P. Direct evidence that the FimH protein is the mannose-specific adhesin of Escherichia coli type 1 fimbriae. Infect Immun 58:1995. (Pubitemid 20176404)
18. Russell PW, Orndorff PE. Lesions in two Escherichia coli type 1 pilus genes alter pilus number and length without affecting receptor binding. J Bacteriol 174:5923, 1992.
19. Orndorff PE, Devapali A, Palestrant S, Wyse A, Everett ML, Bollinger RR, Parker W. Immunoglobulin-mediated agglutination of and biofilm formation by Escherichia coli K-12 require the type 1 pilus fiber. Infect Immun 72:1929, 2004.
20. Powell DW. Neuroimmunophysiology of the gastrointestinal mucosa: implications for inflammatory diseases. Trans Am Clin Climatol Assoc 106:124, 1995.
21. Geibel JP. Secretion and absorption by colonic crypts. Annu Rev Physiol 67:471, 2005.
22. Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Applied Environment Microbiol 62:1958, 1996.
23. McGroarty JA, Reid G. Detection of a Lactobacillus substance that inhibits Escherichia coli. Can J Microbiol 34:974, 1988. (Pubitemid 18269302)
24. Christensen HR, Frokiaer H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 168:171, 2002. (Pubitemid 34014116)
25. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 16:658, 2003. (Pubitemid 37296554)
26. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635, 1999.
27. Cooke EM. Properties of strains of Escherichia coli isolated from the faeces of patients with ulcerative colitis, patients with acute diarrhoea and normal persons. J Pathol Bacteriol 95:101, 1968.
28. Nowrouzian FL, Wold AE, Adlerberth I. Escherichia coli strains belonging to phylogenetic group B2 have superior capacity to persist in the intestinal microflora of infants. J Infect Dis 191:1078, 2005 (Pubitemid 40404366)
29. Orndorff PE, Bloch CA. The role of type 1 pili in the pathogenesis of Escherichia coli infections: a short review and some new ideas. Microb Pathogenesis 9:75, 1990.
30. Bloch CA, Stocker BA, Orndorff PE. A key role for type 1 pili in enterobacterial communicability. Mol Microbiol 6:697, 1992.
31. Moshier A, Reddy M, Scannapieco F. Role of type 1 fimbriae in the adhesion of Escherichia coli to salivary mucin and secretory immunoglobulin A. Curr Microbiol 33:200, 1996. (Pubitemid 26272377)
32. Bollinger RR, Everett ML, Palestrant D, Love SD, Lins SS, Parker W. Human secretory IgA may contribute to biofilm formation in the gut. Immunology 109:580, 2003. (Pubitemid 36930175)
33. Palestrant D, Holzknecht ZE, Collins BH, Miller SE, Parker W, Bollinger RR. Secretory IgA associated biofilms are a normal feature of bacterial growth in the mammalian gut. Ultrastructural Pathol 28:23, 2004.
34. Bollinger RR, Everett ML, Wahl SD, Lee YH, Orndorff PE, Parker W. Secretory IgA and mucin-mediated biofilm formation by environmental strains of Escherichia coli: role of type 1 pili. Mol Immunol 43:387, 2004.
35. Servin AL, Coconnier MH. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol 17:741, 2003.
36. Adlerberth I, Ahrne S, Johansson ML, Molin G, Hanson LA, Wold AE. A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. Appl Environment Microbiol 62:2244, 1996. (Pubitemid 26231184)
37. Chauviere G, Coconnier MH, Kerneis S, Fourniat J, Servin AL. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J Gen Microbiol 8:1689, 1992.
38. Blattner FR, Plunkett G III, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y. The complete genome sequence of Escherichia coli K-12. Science 277:1453-1462, 1997. (Pubitemid 27449228)
39. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352, 2000. (Pubitemid 30656052)